Disease · MONDO_0007254
Comparisons in its trials1,000
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 1,000
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tamoxifen Followed by Exemestane vs Exemestane: serious adverse events | 784 of 4,814 | 831 of 4,852 | 9,666 | NCT00036270 | Trial comparisons |
| Palbociclib Plus Endocrine Therapy (Arm A) vs Endocrine Therapy Alone (Arm B): deaths from any cause | 99 of 2,841 | 76 of 2,902 | 5,743 | NCT02513394 | Trial comparisons |
| Palbociclib Plus Endocrine Therapy (Arm A) vs Endocrine Therapy Alone (Arm B): serious adverse events | 369 of 2,841 | 229 of 2,902 | 5,743 | NCT02513394 | Trial comparisons |
| 150 mg Abemaciclib + Endocrine Therapy vs Endocrine Therapy: deaths from any cause | 38 of 2,791 | 36 of 2,800 | 5,591 | NCT03155997 | Trial comparisons |
| 150 mg Abemaciclib + Endocrine Therapy vs Endocrine Therapy: serious adverse events | 344 of 2,791 | 202 of 2,800 | 5,591 | NCT03155997 | Trial comparisons |
| Chemo and Endocrine Therapy vs Endocrine Therapy Alone: deaths from any cause | 161 of 2,487 | 175 of 2,497 | 4,984 | NCT01272037 | Trial comparisons |
| Arm A: Continuous Letrozole vs Arm B: Intermittent Letrozole: deaths from any cause | 170 of 2,426 | 146 of 2,425 | 4,851 | NCT00553410 | Trial comparisons |
| Arm A: Continuous Letrozole vs Arm B: Intermittent Letrozole: serious adverse events | 1,004 of 2,411 | 1,052 of 2,417 | 4,828 | NCT00553410 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 205 of 2,400 | 247 of 2,404 | 4,804 | NCT01358877 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | 792 of 2,364 | 686 of 2,405 | 4,769 | NCT01358877 | Trial comparisons |
| Exemestane vs Tamoxifen: serious adverse events | 383 of 2,320 | 439 of 2,338 | 4,658 | NCT00038467 | Trial comparisons |
| Chemo and Endocrine Therapy vs Endocrine Therapy Alone: serious adverse events | 14 of 2,062 | 9 of 2,342 | 4,404 | NCT01272037 | Trial comparisons |
| Letrozole vs Anastrozole: serious adverse events | 486 of 2,049 | 520 of 2,062 | 4,111 | NCT00248170 | Trial comparisons |
| Letrozole vs Placebo: serious adverse events | 80 of 1,951 | 87 of 1,938 | 3,889 | NCT00382070 | Trial comparisons |
| Arm I vs Arm II: Breast Cancer-specific Mortality | 155 of 1,824 | 160 of 1,825 | 3,649 | NCT01101438 | Trial comparisons |
| Metformin vs Placebo: deaths from any cause | 201 of 1,824 | 198 of 1,825 | 3,649 | NCT01101438 | Trial comparisons |
| Metformin vs Placebo: serious adverse events | 1 of 1,816 | 3 of 1,816 | 3,632 | NCT01101438 | Trial comparisons |
| Arm B: Anastrozol - 1 mg Per Day for 5 Years vs Arm A: Anastrozol - 1 mg Per Day for 2 Years: deaths from any cause | 207 of 1,738 | 207 of 1,732 | 3,470 | NCT00295620 | Trial comparisons |
| Arm B: Anastrozol - 1 mg Per Day for 5 Years vs Arm A: Anastrozol - 1 mg Per Day for 2 Years: serious adverse events | 687 of 1,710 | 452 of 1,705 | 3,415 | NCT00295620 | Trial comparisons |
Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival) | 356 of 1,649 | 352 of 1,649 | 3,298 | NCT00312208 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007254/comparisons